
BEAM
Beam Therapeutics Inc
Biotechnology
Beam Therapeutics Inc (BEAM) Stock News
The latest BEAM headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics presented additional clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society conference. The data from 29 patients showed durable efficacy, improved safety profile, and reduction in neutrophil elastase activity. The company plans to pursue an accelerated FDA approval pathway and expects to initiate a pivotal cohort with approximately 50 additional patients in the second half of 2026.